Novonesis A/S (OTCPK:NVZMF) Q3 2024 Earnings Conference Call November 7, 2024 3:00 AM ET
Company Participants
Tobias Cornelius Björklund – Head, Investor Relations
Ester Baiget – Chief Executive Officer
Rainer Lehmann – Chief Financial Officer
Jacob Paulsen – Executive Vice President, Food & Beverage Biosolutions
Amy Byrick – Executive Vice President, Human Health Biosolutions
Tina Fano – Executive Vice President, Planetary Health Biosolutions
Claus Crone Fuglsang – Chief Scientific Officer
Conference Call Participants
Alex Jones – Bank of America
Thomas Lind Petersen – Nordea
Charles Eden – UBS
Søren Samsøe – SEB
Chetan Udeshi – JPMorgan
Lars Topholm – Carnegie Investment Bank
Nicola Tang – BNP Paribas Exane
Georgina Fraser – Goldman Sachs
Charles Bentley – Jefferies
Operator
Welcome to the Novonesis Interim Report for the First Nine Months of 2024 Conference Call. Throughout, all participants will be in listen-only mode and afterwards there will be a question-and-answer session.
Today, I am pleased to leave the word to Tobias Cornelius Björklund, Head of Investor Relations. Please begin your meeting.
Tobias Cornelius Björklund
Thank you, Operator. And welcome everyone to this Novonesis conference call relating to the nine months trading statement of 2024. My name is Tobias Björklund, as mentioned. I’m heading up Investor Relations here at Novonesis. In this call, our CEO, Ester Baiget; and our CFO, Rainer Lehmann, will review our pro forma sales performance for the first nine months of the year, as well as the outlook for the full year. Attending today’s call, we also have Jacob Paulsen, EVP and — EVP of Food & Beverage Biosolutions; Amy Byrick, EVP of Human Health Biosolutions; Tina Fano, EVP of Planetary Health Biosolutions; and Claus Crone Fuglsang, Chief Scientific Officer. The conference call will take about 45 minutes and then that includes time for Q&A at the end.
If
Read the full article here
